MMV疟疾盒化合物的相对杀菌速率与抗疟作用模式相关
本研究采用生物发光相对杀菌速率(BRRoK)试验,在6和48小时、等效IC50浓度下比较MMV疟疾盒化合物与基准抗疟药的杀细胞效果。结果显示不同作用模式药物的相对杀菌速率从快到慢依次为PfATP4抑制剂>血红蛋白分解抑制剂>DHFR-TS抑制剂>DHODH抑制剂>bc1复合物抑制剂,并发现二氨基甘油和2-氨甲基苯酚骨架具有内在快速杀细胞作用。
要点
- 化合物相对杀菌速率与其作用模式相关,靶点内在速率受药物可及性影响
- 二氨基甘油和2-氨甲基苯酚骨架显示快速杀细胞作用,值得药物化学优化
- BRRoK试验为药物发现提供通量和决策工具
核心结论
- 化合物相对杀菌速率与作用模式相关,靶点内在速率受药物可及性影响。
- 二氨基甘油和2-氨甲基苯酚骨架具有内在快速杀细胞作用。
- BRRoK试验可作为药物发现决策工具支持开发。
研究设计与样本
- 采用生物发光相对杀菌速率(BRRoK)试验,在6和48小时、等效IC50浓度下比较MMV疟疾盒化合物与基准抗疟药的杀细胞效果。
主要发现
- 相对杀菌速率从快到慢依次为:PfATP4抑制剂>寄生虫血红蛋白分解抑制剂>DHFR-TS抑制剂>DHODH抑制剂>bc1复合物抑制剂。
- 核心骨架聚类分析显示二氨基甘油和2-氨甲基苯酚具有内在快速杀细胞作用,而2-苯基苯并咪唑、8-羟基喹啉和三唑并嘧啶作用缓慢。
临床怎么用
- 在药物化学优化效力的同时,可针对某些骨架改善杀菌速率。
- BRRoK试验可用于支持抗疟药物开发 campaign 的决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Rapid rate-of-kill (RoK) is a key parameter in the target candidate profile 1 (TCP1) for the next-generation antimalarial drugs for uncomplicated malaria, termed Single Encounter Radical Cure and Prophylaxis (SERCaP). TCP1 aims to rapidly eliminate the initial parasite burden, ideally as fast as artesunate, but minimally as fast as chloroquine. Here we explore whether the relative RoK of the Medicine for Malaria Venture (MMV) Malaria Box compounds is linked to their mode of action (MoA) and identify scaffolds of medicinal chemistry interest. METHODS: We used a bioluminescence relative RoK (BRRoK) assay over 6 and 48 h, with exposure to equipotent IC50 concentrations, to compare the cytocidal effects of Malaria Box compounds with those of benchmark antimalarials. RESULTS: BRRoK assay data demonstrate the following relative RoKs, from fast to slow: inhibitors of PfATP4>parasite haemoglobin catabolism>dihydrofolate reductase-thymidylate synthase (DHFR-TS)>dihydroorotate dehydrogenase (DHODH)>bc1 complex. Core-scaffold clustering analyses revealed intrinsic rapid cytocidal action for diamino-glycerols and 2-(aminomethyl)phenol, but slow action for 2-phenylbenz-imidazoles, 8-hydroxyquinolines and triazolopyrimidines. CONCLUSIONS: This study provides proof of principle that a compound's RoK is related to its MoA and that the target's intrinsic RoK is also modified by factors affecting a drug's access to it. Our findings highlight that as we use medicinal chemistry to improve potency, we can also improve the RoK for some scaffolds. Our BRRoK assay provides the necessary throughput for drug discovery and a critical decision-making tool to support development campaigns. Finally, two scaffolds, diamino-glycerols and 2-phenylbenzimidazoles, exhibit fast cytocidal action, inviting medicinal chemistry improvements towards TCP1 candidates.
引用
- Ullah I, Sharma R, Mete A, et al. The relative rate of kill of the MMV Malaria Box compounds provides links to the mode of antimalarial action and highlights scaffolds of medicinal chemistry interest. J Antimicrob Chemother. 2020. PMID: 31665424. doi:10.1093/jac/dkz443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。